08 February 2022, 8:05 pm. 1 minute
Reuters revealed that the drugmaker has only delivered a small fraction of the 2 billion COVID-19 vaccines it has promised to governments worldwide and has delayed shipments expected in the first quarter to the European Union, Indonesia and the Philippines. The story, with reporting from the United States, Europe and Asia, also revealed how far behind Novavax is in fulfilling its promises to governments and to COVAX, the global vaccine distribution program that plays a key role in supplying the vaccines to low-income countries. Officials in the Philippines said that they are now seeking to trim their Novavax contract, as a longer-than-expected wait for the company’s vaccine led the country to stockpile supply from other drugmakers. Several industry analysts said they are reviewing their 2022 vaccine sales forecasts of around $5 billion for Novavax in light of the news.
Shares in Novavax fell 15% following the report.
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Major Global Story